Sarepta prices $500M common stock offering; preliminary Q3 revenue up 37% to $166.9M

Sarepta Therapeutics, Inc.

Preliminary Q3 2021 net product revenue of ~$166.9M, up from $121.4M in Q3 2020.
Cash, cash equivalents and investments were ~$1.6B as of Sept 30, 2021, down from $1.9B at Dec 31, 2020.
Priced public offering of 6,172,840 shares at $81.00/share for gross proceeds of $500M; net proceeds ~$549.1M.
Underwriters granted 30-day option for additional 925,926 shares, exercised in full; closing expected Oct 18, 2021.
Proceeds to fund clinical trials, commercialization, manufacturing, and potential acquisitions.

item 1.01 item 2.02 item 2.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.